Gut 1994; 35: 1599-1604 Microalbuminuria in inflammatory bowel disease N (8) [Lg/min, mean (SEM), p<0O0001).
Eight patients with active inflammatory bowel disease who were sequentially followed up with measurements of microalbuminuria had significantly lower values, when the disease was inactive (active inflammatory bowel disease 192 (44) v inactive inflammatory bowel disease 64 (14) ,ug/min, p<003). There was a significant correlation with the simple index of Harvey Persistently increased excretion of albumin above normal, which is not detected by the conventional semiquantitative strips test is defined as microalbuminuria. Albuminuria excretion greater than 20 micrograms per minute in a timed overnight urine specimen is diagnostic of microalbuminuria. Microalbuminuria when present in abnormal amounts in diabetic patients predicts diabetic nephropathy and increased incidence of cardiovascular related morbidity and mortality.1-7. Microalbuminuria in patients with hypertension, non-diabetic patients, and the elderly is also indicative of increased morbidity and mortality resulting from cardiovascular events.2 8 9 Microalbuminuria is also described, however, as a non-specific marker for acute illnessl' such as sepsis, trauma, burns"l and ischaemic injuries such as myocardial infarction, most probably as a result of the acute phase response to inflammatory mediators and in this respect it may provide a more longlasting and easily measurable indicator than other acute phase parameters. Microalbuminuria in malignancy may reflect the microvascular response to tumour related mediators and is of prognostic value. 12 The aetiology of inflammatory bowel disease is unknown and its course is unpredictable with high recurrence rates. It has been suggested, however, that inflammatory bowel disease, in particular Crohn's disease, has a vascular aetiology. ' 
SUBJECTS
Ninety five consecutive patients with inflammatory bowel disease were studied prospectively. These consisted of patients attending the outpatient department at St James's Hospital with ulcerative colitis or Crohn's disease confirmed on the basis of endoscopy, histology, and radiology. Fifty two patients had ulcerative colitis and 43 patients had Crohn's disease. Their median age was 42 (range 16-69) years, and they received conventional medical and surgical treatment. All patients recruited in this study who were receiving medical treatment with 5-ASA compounds had been maintained with these drugs for a duration of at least 12 months (sulphasalazine (n= 35), olsalazine (n=33), and mesalazine (n=15)). A group of patients (n= 12) receiving no drugs was studied as drug free disease controls. The nontreatment disease control group included newly diagnosed patients with inflammatory bowel disease and patients with small bowel Crohn's disease who were not receiving any drugs. At their hospital visit clinical disease activity was assessed using the simple index of Harvey and Bradshaw. The disease was considered active if the simple index of Harvey and Bradshaw score was greater than 4. At the same visit samples were taken for routine biochemistry and 10 ml of serum was obtained and saved at -700C for later estimation of amyloid A protein and C reactive protein. Twenty healthy controls also had 12 hours overnight urine collection for microalbuminuria and venesection for serum amyloid-A and C reactive protein estimation. All patients and controls received instructions for 12 hour overnight urine collection starting from 9 pm to 9 am. After completing collection, the urine was received within two hours, the volume was measured, and 30 ml of urine was stored at -20°C for measurement of microalbuminuria. In addition routine urine analysis was performed and estimation of urinary urea, electrolytes, protein, and creatinine clearance was performed. Blood samples were taken within two hours of completing the 12 hour overnight urine collection.
Exclusion criteria Patients aged more than 70 years or with diabetes mellitus, hypertension, renal disease, urinary tract infection, and patients using nonsteroidal anti-inflammatory agents were not recruited in the study. Ten patients were excluded from the study, and four patients failed to complete the protocol.
MEASUREMENT OF SERUM AMYLOID-A AND C REACTIVE PROTEIN
Serum amyloid-A was measured in all patients and controls with a commercially available enzyme linked immunosorbent assay (ELISA) (Biosource International, Camarillo, California). The sensitivity of the assay is 10 ,ug/ml. The intra-assay and interassay coefficients of variation are 8-5% and 9-8%. C reactive protein was measured by the nephelometry method.
MICROALBUMINURIA ASSAY Microalbuminuria was measured in all patients and 20 normal controls using an immunoturbiditimetric method (Microalbs, Ames, Bucks, UK). In this method human albumin reacts with a specific antibody in the presence of polyethylene glycol. As the antibody was present in large excess the precipitated complex produced a turbidity related to the concentration of albumin in the sample. The turbidity was photometrically measured at wavelength 340 nm. Coefficient of variance was less than 3%.
GLUTATHIONE S TRANSFERASE pi
The urinary concentrations of glutathione S transferase pi was measured using a radioimmunoassay supplied by Immundiagnostik GmbH Bensheim, Germany. 18 variables including stool weight (mean of five consecutive days), and neither patients nor evaluating physicians find it convenient. Furthermore, this index requires patients to use a diary card to record symptoms over seven days. This is obviated in the simple index of Crohn's disease activity designed by Harvey and Bradshaw, which is also dependent on subjective variables.21 The platelet count is often increased in active inflammatory bowel disease,28 but difficulty arises when these patients are receiving corticosteroid treatment or other immunosuppressive agents (azathioprine), which cause bone marrow depression and decrease in platelet count. Indium-I1 1 labelled leucocyte scan is the most commonly used radioisotope technique'8-20 and permits faecal excretion studies for the assessment of disease activity. Technical difficulty, expense, the need for collection of stools over four days, and use of radioisotopes are the main disadvantages of faecal indium excretion studies.
Our study has shown that microalbuminuria is a useful disease activity marker for inflammatory bowel disease. Large increases in the concentrations of microalbuminuria were detected in patients with active Crohn's disease and those with active ulcerative colitis, which fell with clinical improvement. A significant correlation was found between microalbuminuria and the clinical disease activity index. Nevertheless, microalbuminuria continues even in remission in patients with inflammatory bowel disease. This may suggest that microalbuminuria could be a highly sensitive indicator of a low level of ongoing inflammation in these patients. Further studies correlating microalbuminuria with histological activity will be necessary to find out if this is the case and these studies are ongoing. Microalbuminuria in inflammatory bowel disease does not result from glomerular or tubular damage as a result of drugs (sulphasalazine, olsalazine, mesalazine), as there is no correlation with drug therapy in patients with active disease. Furthermore, there is no indication of drug induced tubular damage; a sensitive index of tubular dysfunction glutathione S transferase pi29 was measured and found to be negative in all cases tested (data not shown). Using microalbuminuria, however, as an objective disease activity marker in patients in remission maintained with olsalazine, we found significantly lower concentrations compared with those patients in remission and maintained with sulphasalazine and mesalazine. This could possibly suggest that olsalazine treatment results in a remission with lower levels of background inflammation, although further prospective studies are required to confirm this finding. Patients receiving olsalazine for maintenance treatment received a similar dose of 5-ASA (1 g daily) to those receiving mesalazine (1 *2 g daily).
Eight patients with active disease who were followed up with sequential analysis of microalbuminuria showed that when the disease became quiescent concentrations of microalbuminuria decreased significantly. In our study four patients with active disease (ulcerative colitis n=2 and Crohn's colitis n=2, one patient in each group had toxic megacolon) who did not respond to medical treatment and who needed a surgical colectomy had the highest recorded values of microalbuminuria with persistently high concentrations of microalbuminuria (all greater than 312 ,ug/min). Thus microalbuminuria may have a prognostic value and its serial analysis may be helpful in the early recognition of non-responders to medical treatment.
Microalbuminuria has also been reported in acute illness, sepsis, post-trauma, and bums. The underlying mechanism of protein leakage through the kidney in these conditions and inflammatory bowel disease probably results from the increased renal microvasculature permeability in response to increased circulating inflammatory mediators. In recent years there has been considerable interest in the role of inflammatory mediators including interleukin 1, interleukin 2, interleukin 6, and tumour necrosis factor ox in inflammatory bowel disease.30-33 An important part of the acute phase reaction is the modulation of the synthesis of acute phase proteins in the liver by systemic cytokines.34 35 In our study serum amyloid-A correlated with clinical disease activity, however, microalbuminuria correlated poorly with serum amyloid-A.
It has been suggested that the intestinal microvasculature may play an early part in the pathogenesis of inflammatory bowel disease, and Crohn's disease in particular. This hypothesis suggests that an initial vascular insult results in the formation of granulomatous vasculitis, accelerated thrombogenesis, and multifocal gastrointestinal infarction.13 14 We found no evidence of renal damage to suggest that renal vasculitis may have been responsible for microalbuminuria in inflammatory bowel disease patients. All our patients had normal urine analysis, microscopy, creatinine clearance, and estimation of urinary glutathione S transferase pi; a sensitive marker for early renal tubular damage.29
We believe that microalbuminuria may result from the increased renal microvascular permeability in response to increased circulating cytokines. It has been shown in animal models that the cytokines interleukin 1 and tumour necrosis factor cx cause microvascular permeability, which may be either direct or mediated by their effects on neutrophil migration.36 The local tissue damage in the intestine leads to the activation of leucocytes and fibroblasts with resultant release of cytokines such as interleukin 1, interleukin 6, and tumour necrosis factor ax, which may induce a receptor mediated systemic reaction. Microalbuminuria may reflect either the direct effect of the cytokines on the renal matrix molecules or indirect effects mediated through an inflammatory cell infiltrate into the affected kidney. Sulphated glycosaminoglycans have been reported to regulate albumin flux in the glomerulus basement membrane. 
